Stemline Therapeutics (STML) Misses Q4 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- US stock futures steady after tech slump; investors focus on Middle East tensions
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- U.S. debt tops $40 trillion
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Marvell shares jump after giving Google warrants amid custom chip deal
Stemline Therapeutics Reports Fourth Quarter 2014 Financial Results
March 13, 2015 6:04 PM EDTNEW YORK, March 13, 2015 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a clinical stage biopharmaceutical company developing novel drugs targeting cancer stem cells (CSCs) and tumor bulk, today reported financial results for the quarter ended December 31, 2014.
Ivan Bergstein, M.D., Stemline's Chief Executive Officer, commented, "The last few months have been extremely productive for Stemline, highlighted by continued patient enrollment in our SL-401 and SL-701 trials, the in-licensing of SL-801, a novel, reversible XPO1 inhibitor, and the successful completion of a $68 million public offering." Dr. Bergstein continued, "We look forward to an... More
Stemline Therapeutics Reports Fourth Quarter 2014 Financial Results
March 13, 2015 6:04 PM EDTNEW YORK, March 13, 2015 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a clinical stage biopharmaceutical company developing novel drugs targeting cancer stem cells (CSCs) and tumor bulk, today reported financial results for the quarter ended December 31, 2014.
Ivan Bergstein, M.D., Stemline's Chief Executive Officer, commented, "The last few months have been extremely productive for Stemline, highlighted by continued patient enrollment in our SL-401 and SL-701 trials, the in-licensing of SL-801, a novel, reversible XPO1 inhibitor, and the successful completion of a $68 million public offering." Dr. Bergstein continued, "We look forward to an... More
